Optimising Asparaginase Use and Managing Hypersensitivity in Australasia-A Clinical Practice Guideline From the Australian and New Zealand Children's Haematology/Oncology Group.
ANZCHOG reports an Australasian clinical practice guideline covering asparaginase product selection, serum activity monitoring, hypersensitivity management, and responses to suboptimal asparagine depletion in children, adolescents, and young adults with acute lymphoblastic leukaemia or lymphoblastic lymphoma.
Open original publication →What the AI sees
ANZCHOG reports an Australasian clinical practice guideline covering asparaginase product selection, serum activity monitoring, hypersensitivity management, and responses to suboptimal asparagine depletion in children, adolescents, and young adults with acute lymphoblastic leukaemia or lymphoblastic lymphoma.
Research significance
The record supports standardising asparaginase monitoring and hypersensitivity management to help maintain adequate treatment exposure; it is reasonable but not demonstrated here to infer that implementation could reduce avoidable underexposure and improve outcomes or toxicity management.
Source abstract
BACKGROUND: Asparaginase is a critical component of modern multi-agent chemotherapy regimens for paediatric acute lymphoblastic leukaemia and lymphoblastic lymphoma, with inadequate exposure leading to inferior patient outcomes. OBJECTIVES: To develop a clinical practice guideline for the use of asparaginase products in the Australasian context. METHODS: This clinical practice guideline was developed following consultation and a review of the available published data and is designed to standardise treatment across the region. RESULTS: This paper reports the position of the Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) on key areas including established and new asparaginase products and their use in Australasia, monitoring and interpretation of serum asparaginase activity, care in the setting of hypersensitivity and management of suboptimal asparagine depletion. CONCLUSIONS: This clinical practice guideline will assist clinicians in the Australasian region who provide care to children, adolescents and young adults receiving asparaginase therapy.